

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

BeatO raises Rs 42 Cr in funding

07 July 2021 | News

The funds will be utilised across two key areas – growth in subscriber base across multiple channels and geographies, and product enhancement to provide care for other cardiometabolic conditions



Digital care ecosystem for chronic condition management, BeatO, has raised Rs 42 crore in funding led by US-based venture capital firm W Health Ventures. With this new funding, BeatO has raised Rs 75 crore over the last year across its Series A and Pre-series B rounds. The fresh funds will be utilised across two key areas – growth in subscriber base across multiple channels and geographies, and product enhancement to provide care for other cardiometabolic conditions. The funding also saw participation from PharmEasy (a Threpsi Solutions brand), Merisis VP and existing investors Orios VP, Leo Capital and others.

BeatO's digital health platform combines real-time monitoring via its IoT-connected devices and app ecosystem to provide AI-driven personalized insights and proactive intervention by doctors and health coaches to patients with chronic conditions such as diabetes.

Gautam Chopra, Co-Founder & CEO, BeatO said, "We welcome our new partners in our exciting journey as we continue to address this large problem and positively impact millions of lives".

"We're impressed with BeatO's unparalleled patient experience and outstanding clinical results. The company's exponential growth is driven by its ability to transcend geographical and socio-economic barriers to also reach tier-II and tier-III cities in India, where access to diabetes care is generally limited," said Dr Pankaj Jethwani, Executive Vice President, W Health Ventures.